Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Antihypertensive Medication Use in Older Patients Transitioning from Chronic Kidney Disease to End-Stage Renal Disease on Dialysis.

Chang TI, Zheng Y, Montez-Rath ME, Winkelmayer WC.

Clin J Am Soc Nephrol. 2016 Aug 8;11(8):1401-12. doi: 10.2215/CJN.10611015. Epub 2016 Jun 27.

PMID:
27354656
2.

Short and Long-Term Effects of the Angiotensin II Receptor Blocker Irbesartan on Intradialytic Central Hemodynamics: A Randomized Double-Blind Placebo-Controlled One-Year Intervention Trial (the SAFIR Study).

Peters CD, Kjaergaard KD, Jensen JD, Christensen KL, Strandhave C, Tietze IN, Novosel MK, Bibby BM, Jespersen B.

PLoS One. 2015 Jun 1;10(6):e0126882. doi: 10.1371/journal.pone.0126882. eCollection 2015.

3.

Left ventricular dysfunction in the haemodialysis population.

Sood MM, Pauly RP, Rigatto C, Komenda P.

NDT Plus. 2008 Aug;1(4):199-205. doi: 10.1093/ndtplus/sfn074.

4.

Pharmacological and non pharmacological strategies in the management of coronary artery disease and chronic kidney disease.

Agrawal H, Aggarwal K, Littrell R, Velagapudi P, Turagam MK, Mittal M, Alpert MA.

Curr Cardiol Rev. 2015;11(3):261-9. Review.

5.

Use of renin-angiotensin system inhibitors is associated with reduction of fracture risk in hemodialysis patients.

Yamamoto S, Kido R, Onishi Y, Fukuma S, Akizawa T, Fukagawa M, Kazama JJ, Narita I, Fukuhara S.

PLoS One. 2015 Apr 13;10(4):e0122691. doi: 10.1371/journal.pone.0122691. eCollection 2015.

6.

An update on coronary artery disease and chronic kidney disease.

Afsar B, Turkmen K, Covic A, Kanbay M.

Int J Nephrol. 2014;2014:767424. doi: 10.1155/2014/767424. Epub 2014 Mar 10. Review.

7.

Assessment and management of hypertension in patients on dialysis.

Agarwal R, Flynn J, Pogue V, Rahman M, Reisin E, Weir MR.

J Am Soc Nephrol. 2014 Aug;25(8):1630-46. doi: 10.1681/ASN.2013060601. Epub 2014 Apr 3. Review.

8.

Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis.

Morishita Y, Kusano E, Nagata D.

Open Cardiovasc Med J. 2014 Feb 7;8:6-11. doi: 10.2174/1874192401408010006. eCollection 2014.

9.

Cardiorenal syndrome type 4: a review.

Clementi A, Virzì GM, Goh CY, Cruz DN, Granata A, Vescovo G, Ronco C.

Cardiorenal Med. 2013 Apr;3(1):63-70. doi: 10.1159/000350397.

10.

Action of irbesartan on blood pressure and glucose/lipid metabolism, in hemodialysis patients with hypertension.

Onishi A, Morishita Y, Watanabe M, Numata A, Tezuka M, Okuda K, Tsunematsu S, Sugaya Y, Hashimoto S, Kusano E.

Int J Gen Med. 2013 May 28;6:405-11. doi: 10.2147/IJGM.S43850. Print 2013.

11.

Comparative effectiveness research in heart failure therapies: women, elderly patients, and patients with kidney disease.

Shah RU, Chang TI, Fonarow GC.

Heart Fail Clin. 2013 Jan;9(1):79-92. doi: 10.1016/j.hfc.2012.09.003. Epub 2012 Oct 16. Review. No abstract available.

12.

Pharmacologic management of chronic reno-cardiac syndrome.

Hawwa N, Schreiber MJ Jr, Tang WH.

Curr Heart Fail Rep. 2013 Mar;10(1):54-62. doi: 10.1007/s11897-012-0122-8. Review.

13.

Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis.

Yamamoto S, Yancey PG, Zuo Y, Ma LJ, Kaseda R, Fogo AB, Ichikawa I, Linton MF, Fazio S, Kon V.

Arterioscler Thromb Vasc Biol. 2011 Dec;31(12):2856-64. doi: 10.1161/ATVBAHA.111.237198. Epub 2011 Oct 6.

14.

Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients.

Chan KE, Ikizler TA, Gamboa JL, Yu C, Hakim RM, Brown NJ.

Kidney Int. 2011 Nov;80(9):978-85. doi: 10.1038/ki.2011.228. Epub 2011 Jul 20.

15.

Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials.

Bangalore S, Kumar S, Wetterslev J, Messerli FH.

BMJ. 2011 Apr 26;342:d2234. doi: 10.1136/bmj.d2234. Review.

16.

Hypertension and hemodialysis: pathophysiology and outcomes in adult and pediatric populations.

Van Buren PN, Inrig JK.

Pediatr Nephrol. 2012 Mar;27(3):339-50. doi: 10.1007/s00467-011-1775-3. Epub 2011 Feb 1. Review.

17.

Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice.

Yamamoto S, Zuo Y, Ma J, Yancey PG, Hunley TE, Motojima M, Fogo AB, Linton MF, Fazio S, Ichikawa I, Kon V.

Nephrol Dial Transplant. 2011 Aug;26(8):2491-7. doi: 10.1093/ndt/gfq759. Epub 2011 Jan 18.

18.

Atherosclerosis in chronic kidney disease: the role of macrophages.

Kon V, Linton MF, Fazio S.

Nat Rev Nephrol. 2011 Jan;7(1):45-54. doi: 10.1038/nrneph.2010.157. Epub 2010 Nov 23. Review.

19.

Can we reduce the cardiovascular risk in peritoneal dialysis patients?

Chiu YW, Mehrotra R.

Indian J Nephrol. 2010 Apr;20(2):59-67. doi: 10.4103/0971-4065.65296.

20.

Antihypertensive agents in hemodialysis patients: a current perspective.

Inrig JK.

Semin Dial. 2010 May-Jun;23(3):290-7. doi: 10.1111/j.1525-139X.2009.00697.x. Epub 2010 Mar 29. Review.

Items per page

Supplemental Content

Write to the Help Desk